Seeking Alpha
 

Stryker Corporation (SYK)

- NYSE
  • Thu, Aug. 6, 3:38 PM
    • The FDA clears Stryker's (SYK -1.9%) 510(k) application seeking clearance for its Mako total knee application. The approval adds to the company's Mako offering of partial knee and total hip applications and enables it to offer a comprehensive solution in its robotic reconstructive service line.
    • A limited market release will commence by year end.
    | Thu, Aug. 6, 3:38 PM | Comment!
  • Thu, Jul. 23, 4:33 PM
    • Stryker (NYSE:SYK): Q2 EPS of $1.20 beats by $0.03.
    • Revenue of $2.43B (+3.0% Y/Y) in-line.
    • Press Release
    | Thu, Jul. 23, 4:33 PM | Comment!
  • Thu, Jul. 23, 4:18 PM
    • Stryker (NYSE:SYK) Q2 results ($M): Total Revenues: 2,432 (+2.9%); Orthopedics: 1,035 (+0.7%); Medsurg: 939 (-8.7%); Neurotech & Spine: 458 (+6.5%).
    • Net Income: 392 (+82.3%); EPS: 1.03 (+83.9%); CF Ops: 357 (-2.5%).
    • 2015 Guidance: Organic sales growth: 5.5 - 6.5%; Non-GAAP EPS: $5.06 - 5.12 from $4.95 - 5.10. If forex holds at present levels, EPS will be negatively impacted ~$0.25.
    • Q3 Guidance: Non-GAAP EPS: $1.20 - 1.25.
    | Thu, Jul. 23, 4:18 PM | Comment!
  • Wed, Jul. 22, 12:52 PM
    • Stryker (SYK -0.6%) reports tomorrow after the close. Consensus view is EPS of $1.17 (+109%) on revenues of $2.4B (+2%).
    | Wed, Jul. 22, 12:52 PM | Comment!
  • Mon, Jul. 20, 8:37 AM
    • Stryker (NYSE:SYK) acquires Kayseri, Turkey-based Muka Metal A.S., a maker of hospital beds, stretchers and related patient room furniture and accessories, for an undisclosed sum. The transaction, expected to be neutral to Stryker's 2015 EPS, should close in Q3.
    • Timothy Scannell, Stryker Group President, MedSurg and Neurotechnology, says, " The acquisition of Muka aligns with our strategy to expand our global presence through existing channels with an established and trusted brand. This acquisition will bolster Stryker Medical's bed and stretcher offerings and is a compelling opportunity to drive growth in Turkey and other regions around the world."
    | Mon, Jul. 20, 8:37 AM | Comment!
  • Tue, Apr. 21, 6:16 PM
    • Stryker (NYSE:SYK) Q1 results ($M): Total Revenues: 2,379 (+3.2%); Net Income: 224 (+220.0%); GAAP EPS: 0.58 (+222.2%); CF Ops: 380 (+84.5%); Quick Assets: 4,263 (+5.3%).
    • Sales by segment: Orthopedics: 1,023 (+2.4%), Knees: 345 (-0.9%), Hips: 312 (-1.9%), Trauma & Extremities: 313 (+8.7%); Medsurg: 927 (+4.6%), Instruments: 346 (+0.9%), Endoscopy: 321 (+2.9%), Medical: 205 (+13.3%); Neurotech & Spine: 429 (+2.1%), Neurotechnology: 252 (+3.7%), Spine: 177 (0.0%).
    • Medsurg sales growth has decelerated the past three quarters: 23.6%, 16.3%, 12.1%, 4.6%.
    • Q2 Guidance: Non-GAAP EPS: $1.15 - 1.20.
    • 2015 Guidance: Organic sales growth: 5 - 6%; Non-GAAP EPS: $4.95 - 5.10 from $4.90 - 5.00.
    • If foreign currency exchange rates remain unchanged, sales in Q2 and 2015 will be negatively impacted by 3.5 - 4.5% and non-GAAP EPS by $0.25 - 0.30, half of which will be in H1.
    | Tue, Apr. 21, 6:16 PM | Comment!
  • Tue, Apr. 21, 4:49 PM
    • Stryker (NYSE:SYK): Q1 EPS of $1.11 beats by $0.03.
    • Revenue of $2.38B (+3.5% Y/Y) in-line.
    • Press Release
    | Tue, Apr. 21, 4:49 PM | Comment!
  • Tue, Apr. 21, 1:34 PM
    • Stryker (SYK +1.3%) will report Q1 results after today's close. Consensus view is EPS of $1.08 on revenues of $2.4B.
    | Tue, Apr. 21, 1:34 PM | Comment!
  • Mon, Apr. 20, 5:35 PM
  • Wed, Apr. 8, 1:38 PM
    • Cytori Therapeutics (CYTX -1.5%) rated Buy with a $7 (425% upside) price target by Maxim Group.
    • Sagent Pharmaceuticals (SGNT +9.2%) rated Buy with a $29 (13% upside) price target by Deutsche Bank.
    • Mylan (MYL +15.6%) rated Overweight with a $70 (2% upside) price target by JP Morgan.
    • Akorn (AKRX +3.7%) rated Buy with a $55 (11% upside) price target by Deutsche Bank.
    • OvaScience (OVAS +1.4%) rated Outperform with a $60 (102% upside) price target by Oppenheimer.
    • Impax Laboratories (IPXL +3.2%) rated Hold with a $50 (flat) price target by Deutsche Bank.
    • Catamaran (CTRX) downgraded to Hold with a $61.50 (4% upside) price target by Jefferies.
    • NewLink Genetics (NLNK +4.4%) downgraded to Hold with a $50 (11% downside risk) price target by Jefferies.
    • Stryker (SYK +0.4%) downgraded to Underweight with a $92 (flat) price target by Barclays.
    | Wed, Apr. 8, 1:38 PM | 5 Comments
  • Thu, Apr. 2, 1:23 PM
    • Retrophin (RTRX +3.7%) rated Outperform with a $48 (98% upside) price target by Leerink Partners.
    • OvaScience (OVAS +8.7%) rated Outperform with a $60 (82% upside) price target by Oppenheimer.
    • OxiGENE (OXGN -0.7%) rated Buy with a $6 (314% upside) price target by H.C. Wainwright.
    • Esperion Therapeutics (ESPR -4.5%) rated Buy with a $140 (40% upside) price target by UBS.
    • Trevena (TRVN -2.3%) rated Outperform with a $15 (110% upside) price target by Wedbush.
    • NewLink Genetics (NLNK -2.3%) downgraded to Hold with a $50 (4% downside risk) price target by Jefferies.
    • Stryker (SYK +0.2%) downgraded to Underweight with a $92 (1% upside) price target by Barclays.
    • Universal Health Services (UHS +2.7%) downgraded to Underperform with a $98 (16% downside risk) price target by Sterne Agee.
    | Thu, Apr. 2, 1:23 PM | 3 Comments
  • Tue, Mar. 3, 8:58 AM
    • Stryker's (NYSE:SYK) Board of Directors authorizes a new $2B share repurchase program. Combining the $583M remaining under the existing authorization brings the total buyback amount up to $2.583B.
    | Tue, Mar. 3, 8:58 AM | Comment!
  • Mon, Feb. 9, 5:37 PM
    | Mon, Feb. 9, 5:37 PM | 8 Comments
  • Mon, Feb. 9, 12:21 PM
    • The following are healthcare companies whose after-tax margins have expanded the past three quarters and trade at least 500K shares per day:
    • (ACOR -0.7%)(BCR -1.5%)(BIIB -0.2%)(CAH -1.2%)(CPHD +1.3%)(EVHC -1.6%)(ILMN +0.7%)(JAZZ -1.7%)(LCI +7.3%)(MNK -0.5%)(SHPG -2.9%)(SYK -0.2%)(TMO -0.7%)(UTHR +1.4%)(VRX).
    • This is not a list of "Buy" recommendations, but rather a targeted list of firms that may be suitable for more in-depth research.
    | Mon, Feb. 9, 12:21 PM | 3 Comments
  • Wed, Jan. 28, 1:54 AM
    • "We do plan to put our money to work," announced Stryker (NYSE:SYK) CEO Kevin Lobo on the company's Q4 earnings conference call. "Right now we are pursuing the acquisition deal flow, and we'll see what happens."
    • The company was recently rumored to have been preparing a bid for Smith & Nephew, although he gave no hint that any sort of deal was imminent.
    • Q4 net income fell 33% to $260M, hurt by costs for product recalls and a new regional headquarters in Europe.
    • SYK -0.4% AH
    | Wed, Jan. 28, 1:54 AM | Comment!
  • Tue, Jan. 27, 4:54 PM
    • Stryker (NYSE:SYK): Q4 EPS of $1.44 misses by $0.01.
    • Revenue of $2.62B (+6.1% Y/Y) in-line.
    • Press Release
    | Tue, Jan. 27, 4:54 PM | Comment!
Visit Seeking Alpha's
SYK vs. ETF Alternatives
Company Description
Stryker Corporation is a medical technology company. The Company offers medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products.